Diabetes drug with a novel approach approved by USFDA

The U.S. Food and Drug Administration approved Farxiga (dapaglifozin) tablets aimed at improving the glycemic control in conjunction with diet and exercise, in adults with type 2 diabetes. This drug by the drug company Bristol-Myers Squibb and AtraZeneca has taken a new approach in the area of reducing blood glucose levels.

Farxiga (dapaglifozin) tablets are to be taken once a day and are aimed at helping patients to reduce their blood glucose levels by eliminating excess glucose through urine. The anti-diabetes medications so far used aimed at reducing the blood sugar level by reducing the absorption of glucose from food. These new tablets have a novel approach and can prove to be innovative in the treatment of type 2diabetes.

This drug is considered to belong to the SGLT2 drugs and Invokana from Johnson and Johnson has received USFDA approval so far. Thus Farxiga (dapaglifozin) tablets stand second in their class. The present approval is a successful return for the drug as it was rejected last year due to possible association with liver toxicity and bladder cancer.